Mr. William N. Anderson, also known as Bill, serves as Head of North American Commercial Operations and Director at Genentech, Inc. Mr. Anderson has been Chief Executive Officer of Roche Pharmaceuticals at Roche Holding AG since January 01, 2019. He served as Chief Executive Officer of Genentech since 2017 until March 1, 2019. Mr. Anderson served as Senior Vice President Sales and Marketing - Oncology at Genentech Inc. He served as Senior Vice President of Sales & Marketing for Immunology of Genentech Inc. He joined Roche in 2006 leading the Immunology Business Unit in Genentech and then took responsibility for Oncology Sales and Marketing. In 2013, he was appointed Head of Global Product Strategy. Mr. Anderson served as Vice President of Sales & Marketing for Immunology of Genentech Inc. since April 2006. Mr. Anderson was responsible for leading the sales and marketing activities for RAPTIVA(R) (efalizumab), Xolair(R) (Omalizumab), Rituxan (R) (Rituximab) Immunology and the Immunology pipeline products. He served as Vice President and General Manager of Neurology Business Unit of Biogen Idec. He served as Vice President of Finance - Business Planning of Biogen Idec. While at Biogen Idec, he held leadership roles in the United Kingdom and Ireland. He held marketing and business development roles at Raychem Corporation. Mr. Anderson holds a Bachelor of Science in chemical engineering from the University of Texas, Austin, and Master of Science degrees in management and chemical engineering from the Massachusetts Institute of Technology.